Medicare’s position on Wegovy changed meaningfully in 2024, and the details matter for millions of beneficiaries facing obesity and cardiovascular disease. Does Medicare cover Wegovy depends on which indication it is prescribed for and which Part D plan you are enrolled in. Weight-loss-only prescriptions remain largely excluded; cardiovascular risk reduction prescriptions became covered starting with the 2024 CMS guidance update. Here is the complete picture for 2026.
The Traditional Medicare Exclusion for Weight-Loss Drugs
When Medicare Part D was created in 2003, Congress explicitly excluded several drug categories from required coverage, including drugs used for weight loss. For two decades, that meant Medicare did not cover Wegovy, Saxenda, phentermine, Qsymia, or any other weight-loss medication. This was not a clinical decision — it was a statutory one written into the original Part D law.
The Centers for Medicare and Medicaid Services reaffirmed this exclusion as recently as 2023. Only a change in a drug’s FDA indication — turning it from a “weight-loss drug” into something else — could open the door to coverage under the existing statute. That is exactly what happened with Wegovy in 2024.
The March 2024 Cardiovascular Indication
In March 2024, the FDA approved Wegovy for reducing the risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight. This new indication, based on the SELECT trial published in the New England Journal of Medicine, was a landmark — it was the first time a GLP-1 medication was approved specifically for cardiovascular risk reduction in non-diabetic patients.
Shortly after the FDA approval, CMS issued guidance indicating that Part D plans could cover Wegovy when prescribed for this new cardiovascular indication because the medication was no longer being used purely for weight loss. The prescribing clinician must document the cardiovascular indication for coverage to apply.
Who Qualifies Under the New Medicare Coverage
To qualify for Wegovy under Medicare Part D in 2026, a patient generally needs: established cardiovascular disease (prior myocardial infarction, stroke, symptomatic peripheral artery disease, or established coronary artery disease), and either obesity (BMI 30+) or overweight (BMI 27-29.9). Prescribing clinicians must document both conditions in the medical record for the prior authorization to be approved.
Patients with obesity but without established cardiovascular disease generally do not qualify under the cardiovascular indication, even though they may clinically benefit from Wegovy. The statutory weight-loss exclusion still applies to them. Some patients pursue Saxenda or Zepbound instead, though these also typically are not covered by Medicare. Related: Wegovy Medicare guide.
How Part D Plans Are Handling Coverage
Individual Medicare Part D plans have flexibility in implementing the CMS guidance. By 2026, most standalone Part D plans and Medicare Advantage prescription drug plans have added Wegovy to their formularies with prior authorization requirements tied to the cardiovascular indication. Coverage tier varies — some plans list Wegovy as a Tier 3 specialty drug, others as Tier 4.
Prior authorization typically requires documentation of the cardiovascular indication (ICD-10 codes for MI, stroke, PAD, or established CAD), BMI, and prescribing clinician attestation. PBMs handling Part D plans — CVS Caremark, Express Scripts, Humana Pharmacy Solutions, and OptumRx — each have slightly different forms but similar substantive requirements.
The 2026 Medicare Part D Out-of-Pocket Cap
One of the most important changes for Medicare beneficiaries is the $2,000 annual out-of-pocket cap on Part D prescription drug costs, which took full effect in 2025 and applies in 2026. This means no Medicare patient should pay more than $2,000 per year for covered prescriptions, including Wegovy if it is covered under their plan’s formulary.
Before the cap, Medicare patients could face thousands of dollars in coverage-gap (donut hole) costs on high-priced specialty drugs. The donut hole is effectively eliminated in 2026. Beneficiaries can also opt into the Medicare Prescription Payment Plan, which spreads out-of-pocket costs evenly across the year rather than requiring large payments upfront.
Medicare Advantage Plan Variations
Medicare Advantage (Part C) plans include prescription drug coverage through the same Part D framework but with plan-specific formularies. Some Medicare Advantage plans have historically been more restrictive than standalone Part D, while others offer broader coverage as a competitive differentiator. Compare Wegovy coverage specifically when evaluating Advantage plans during open enrollment.
The $2,000 out-of-pocket cap applies equally to Medicare Advantage plans. If Wegovy is on your Advantage plan’s formulary and you have the documented cardiovascular indication, your annual out-of-pocket cost is capped. Check plan details at Medicare.gov’s plan finder tool during open enrollment (October 15 to December 7).
What to Do If Denied
Medicare denial appeals follow a structured process. First is a redetermination by your Part D plan, which must be requested within 60 days of the denial and decided within 7 days. If still denied, a reconsideration by an independent review entity (IRE) is the second step. Higher levels include an Administrative Law Judge hearing and ultimately federal court review.
Most successful appeals at the plan level come from additional documentation — specifically, records showing the cardiovascular indication is well-supported. Work with your prescriber to gather hospital discharge summaries, cardiologist notes, and imaging reports that document your cardiovascular disease history.
Frequently Asked Questions
Does Medicare cover Wegovy for weight loss alone?
No. The statutory exclusion of weight-loss medications from Medicare Part D still applies. Coverage is only available when Wegovy is prescribed for the FDA-approved cardiovascular risk reduction indication in eligible patients.
How do I know if I qualify for Wegovy under Medicare?
You need established cardiovascular disease (prior MI, stroke, PAD, or established CAD), either obesity (BMI 30+) or overweight (BMI 27+), and a prescriber willing to document both conditions. Your cardiologist or primary care physician is typically best positioned to assess eligibility.
How much will Wegovy cost under Medicare in 2026?
With the $2,000 out-of-pocket cap, your maximum annual cost is capped regardless of Wegovy’s list price. Monthly costs vary depending on your plan’s copay or coinsurance structure, but the annual total is limited. Enrolling in the Medicare Prescription Payment Plan can spread these costs evenly through the year.
Can my Medicare Advantage plan cover Wegovy differently?
Yes. Medicare Advantage plans set their own formularies within Part D rules. Some cover Wegovy at lower tiers, others exclude it entirely if the cardiovascular indication is not documented. Compare plans during open enrollment at Medicare.gov.
What if I have Medicare and Medicaid both?
Dual-eligible beneficiaries have Medicare as primary prescription coverage and Medicaid as secondary. Medicaid may cover copays that Medicare charges for Wegovy. See our Medicaid GLP-1 coverage guide for additional context.
Your Next Step With Medicare and Wegovy
Check your current Part D or Medicare Advantage plan’s formulary for Wegovy. If you have cardiovascular disease history and obesity, ask your cardiologist or primary care doctor whether you qualify under the cardiovascular indication. Gather documentation before submitting a prior authorization — thoroughness at the first submission saves weeks of appeal work.
For broader healthcare policy context, the healthcare policy pillar and our Wegovy Medicare breakdown cover the 2026 Part D changes in detail. The landscape is improving for patients who qualify — but knowing the exact rules is essential for actually accessing coverage.